Kenneth Schultz
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2022First federal award
$13.8MFederal grants as PI19 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
19 awards · $13.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | STTR Phase II Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease | $897K | Trethera Corp |
| Aug 11, 2026 | NIH | SBIR Phase II Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus | $995K | Trethera Corp |
| Aug 5, 2026 | NIH | SBIR Phase II Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors | $1.1M | Trethera Corp |
| Sep 5, 2025 | NIH | SBIR Phase II Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through murine studies to enable further clinical advancement in non-small-cell lung cancer | $407K | Trethera Corp |
| Sep 2, 2025 | NIH | STTR Phase II Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease | $905K | Trethera Corp |
| Aug 18, 2025 | NIH | SBIR Phase II Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors | $1.1M | Trethera Corp |
| Aug 7, 2025 | NIH | SBIR Phase II Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus | $995K | Trethera Corp |
| Jul 15, 2025 | NIH | SBIR Phase II Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM) | $1.0M | Trethera Corp |
| Feb 14, 2025 | NIH | STTR Phase II Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis | $622K | Trethera Corp |
| Jul 5, 2024 | NIH | STTR Phase I Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM) | $297K | Trethera Corp |
| Jul 2, 2024 | NIH | SBIR Phase II Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM) | $1.1M | Trethera Corp |
| May 22, 2024 | NIH | SBIR Phase II Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types | $697K | Trethera Corp |
| May 14, 2024 | NIH | STTR Phase I Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus | $306K | Trethera Corp |
| Feb 8, 2024 | NIH | STTR Phase II Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis | $616K | Trethera Corp |
| Sep 19, 2023 | NIH | STTR Phase I Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease | $395K | Trethera Corp |
| Jul 31, 2023 | NIH | STTR Phase I Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM) | $304K | Trethera Corp |
| Jun 21, 2023 | NIH | STTR Phase I Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus | $305K | Trethera Corp |
| May 30, 2023 | NIH | SBIR Phase II Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types | $1.3M | Trethera Corp |
| Sep 15, 2022 | NIH | STTR Phase II Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis | $368K | Trethera Corp |
Peer ranks
Federal funding#22
Awards as PI#21
Patents#273
Companies
- Trethera CorpLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.